FAQ Library

FAQ Library published on August 9, 2017
Join Dr. McCarthy as he discusses which patients are likely to have a very fulminant or aggressive relapse, and how to risk-stratify these patients from diagnosis to prognosis.
FAQ Library published on July 26, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the two approved monoclonal antibodies, elotuzumab and daratumumab.
FAQ Library published on July 19, 2017
Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with the only approved HDAC inhibitor, panobinostat.
FAQ Library published on July 12, 2017
Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the three approved proteasome inhibitors, carfilzomib, bortezomib, and ixazomib.
FAQ Library published on July 5, 2017
Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with immunomodulatory agents.
FAQ Library published on June 28, 2017
Dr. Philip McCarthy discusses which patients are transplant-eligible and what factors may limit their options.
FAQ Library published on June 14, 2017
Dr. Nooka discusses the crucial steps in identifying if your myeloma patient with cardiac history should receive carfilzomib and if so, when.
FAQ Library published on May 10, 2017
Join Dr. Usmani as he recommends the steps community oncologists should take to differentiate between, and provide ideal follow-up to, MGUS and smoldering MM patients.
FAQ Library published on April 12, 2017
Join Dr. Orlowski as he explains when to use daratumumab-lenalidomide-dexamethasone versus daratumumab-bortezomib-dexamethasone in clinical practice with multiple myeloma patients.
FAQ Library published on March 8, 2017
Join Dr. Usmani as he details the lab, biopsy-specific, and imaging-specific tests the community oncologist needs to consider when establishing a multiple myeloma diagnosis.
Page 1 of 12
Results 1 - 10 of 114